CG Oncology (CGON) Institutional Ownership

26.56% of CG Oncology's stock is owned by institutional investors. Learn more on CGON's institutional investor holdings.

Of the 183 institutional investors that purchased CG Oncology's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Wellington Management Group LLP ($7.42M), BlackRock Inc. ($6.26M), California State Teachers Retirement System ($4.10M), Bank of America Corp DE ($2.68M), Foresite Capital Management VI LLC ($2.22M), Price T Rowe Associates Inc. MD ($2.21M), and Seven Fleet Capital Management LP ($1.89M).

Institutional investors have bought a total of 30,686,362 shares in the last 24 months. This purchase volume represents approximately $1.70B in transactions.

Of the 57 institutional investors that sold CG Oncology's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Braidwell LP ($1.41M), Orbimed Advisors LLC ($1.08M), Bank of America Corp DE ($988.42K), Pictet Asset Management Holding SA ($951.52K), Millennium Management LLC ($706.79K), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC ($379.45K), and ADAR1 Capital Management LLC ($346.74K).

Institutional investors have sold a total of 8,674,478 shares in the last 24 months. This volume of shares sold represents approximately $426.81M in transactions.